InvestorsHub Logo
Followers 71
Posts 7941
Boards Moderated 0
Alias Born 01/29/2015

Re: drt1111 post# 4280

Sunday, 10/21/2018 11:16:41 PM

Sunday, October 21, 2018 11:16:41 PM

Post# of 16698
Being that this is your first post @ Breathtec...I'd imagine you're not an investor? What I've always noted is Cannabix and Breathtec share the same tech,. It's never been a valid reason IMO not to own both. Yeah...hindsight is 20/20 and who knew Breathtec would end up where it is based on the same management team as Cannabix (Kal calls the shots @ both). One company executes a plan (Cannabix). The other company executes it's shareholders (commoners). We now hold out hope the bloody torturing of Breathtec shareholders is over.

To your question of what's good about Yost @ Owlstone Medical - remains a Crystal Ball Theory - because management has yet to explain the relationship from a common shareholder point of view. One can only hope it will bode well for Cannabix to collaborate with a primary competitor of Breath Technology. However, if I had to pitch my best Crystal Ball Theory - I would point to the News Release of August 2, 2018:

Breathtec to Open New Drug Development Division,
Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.

The Company is committed to and will continue to advance the research and development program for its FAIMS technology and will be providing an update to the market on its progress shortly.

Furthermore, here's the language in the October 2018 Monthly Report for the month ending in September 2018:

Management is also completing its global review of the competitivelandscape of potentially competing POC devices for both collection andanalysis of breath for medical screening and diagnostic purposes.

The Company has identified a third party research and technology
development provider in order to advance the speed of the Company’s
FAIMS prototype device program. The Company has been working on a
research agreement draft.

There's quite a bit here that needs to be adressed IMO. Including 4 news releases since August 2, 2018 and none have mentioned FAIMS. Therefore, given the Nash Pharma deal is now a done deal, I'd guess the next news release may provide an update on POC FAIMS Breathalyzer. Maybe, Yosts appointment to Owlstone Medical will be a part of the overall startegy @ Breathtec moving forward?

Just 1 opinion,

/////AMG

P.S. It's thus far been one helluva road for Breathtec. Lot's of PTSD to go around. The upside is there's life and hopefully a green light @ the end of the tunnel here. @ this moment I guess it could be worse? Like Scavaging Like...

Crabs N @ Barrel 1 League Under The Sea



Red Pills